Inventor

John E. Sims

Inventor

Seattle, WA, US

Overview

1990–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 68 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary

C07KPeptides35%

A61KPreparations for medical, dental or toiletry purposes23%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations15%

C12NMicroorganisms or enzymes10%

C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms6%

G01NInvestigating or analysing materials by determining their chemical or physical properties4%

A61BDiagnosis3%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%

G06FElectric digital data processing1%

PatentTitleYear

10,891,278Universal delta set management2021 9,346,870'Antibodies that inhibit TSLP activity'2016 8,871,192'IL-1F8 polypeptides'2014 8,540,993'Methods of treatment using IL-18 receptor antigen binding proteins'2013 8,481,021'IL-1F5 polypeptides'2013 8,444,979'Antibodies that inhibit TSLP activity'2013 8,257,707'IL-18 receptor antigen binding proteins'2012 8,053,233'Host cells expressing IL-18 receptors'2011 8,034,343'Methods of treating inflammatory disorders of the lungs'2011 8,034,771'IL-1F6 polypeptides'2011 7,993,845'ACPL-related assays'2011 7,838,248'ACPL-related assays'2010 7,786,271'Antibodies that inhibit TSLP activity'2010 7,767,793'Antibodies to SIGIRR'2010 7,704,945'IL-18 receptors'2010 7,659,375'Human IL-1 epsilon DNA and polypeptides'2010 7,625,710'Methods for determining 2F1-binding compounds'2009 7,585,949'IL-1 zeta splice variant polypeptide'2009 7,446,171'SIGIRR DNA and polypeptides'2008 7,405,058'Human TSLP polynucleotides'2008 7,304,144'Antibodies binding to human TSLP Polypeptides'2007 7,285,648'IL-1 delta DNA and polypeptides'2007 7,285,634'IL-1 receptor accessory protein'2007 7,270,817'ACPL antibodies and methods of use thereof'2007 7,261,894'Methods of treating inflammatory and/or autoimmune disease'2007 7,250,276'Human IL-1 epsilon DNA and polypeptides'2007 7,235,238'Antibodies that bind receptor protein designated 2F1'2007 7,235,637'IL-1 eta DNA and polypeptides'2007 7,223,565'IL-1 eta DNA and polypeptides'2007 7,217,540'Polynucleotide encoding IL-1 zeta, TDZ.1 isoform polypeptide'2007 7,169,581'IL-18 receptors'2007 7,049,095'DNA encoding IL-1 receptor accessory protein'2006 7,037,675'Nucleic acid molecules encoding SIGIRR polypeptides'2006 7,033,783'Polynucleotide encoding IL-1 zeta polypeptide'2006 7,001,599'Methods for treating inflammation with 2F1 antibody'2006 6,949,359'Human IL-1 epsilon DNA and polypeptides'2005 6,913,893'IL-1/TNF-Î±-activated kinase (ITAK), and methods of making and using the same'2005 6,887,684'MyD88 adapter-like proteins'2005 6,838,290'Methods for screening compounds that affect IL-1 epsilon activity'2005 6,753,166'IL-1 eta DNA and polypeptides'2004 6,692,740'ACPL antibodies'2004 6,693,171'ACPL polypeptides'2004 6,664,077'DNA encoding ACPL'2003 6,589,764'IL-18 receptor fusion proteins'2003 6,555,520'Human TSLP DNA and polypeptides'2003 6,541,232'Polypeptides having kinase activity'2003 6,521,740'Type II Interleukin-1 receptors'2003 6,511,665'Antibodies to interleukin-1 receptors'2003 6,504,023'DNA encoding type II IL-1 receptors'2003 6,492,496'Antibodies to the receptor protein designated 2F1'2002 6,451,760'Treatment of inflammation using a 2F1 polypeptide or an antibody thereto'2002 6,090,918'Receptor protein designated 2F1'2000 6,080,557'IL-1/TNF-.alpha.-activated kinase (ITAK), and methods of making and using the same'2000 5,776,731'DNA encoding type-I interleukin-I receptor-like protein designated 2F1'1998 5,767,064'Soluble type II interleukin-1 receptors and methods'1998 RE035450'Soluble human interleukin-1 receptors, compositions and method of use'1997 5,589,456'Granulocyte-colony stimulating factor receptors'1996 5,576,191'Cytokine that binds ST2'1996 5,492,888'Method of using soluble human interleukin-1 receptors to suppress immune responses'1996 5,488,032'Method of using soluble human interleukin-1 receptors to suppress inflammation'1996 5,464,937'Type II Interleukin-1 receptors'1995 5,422,248'DNA sequences encoding granulocyte-colony stimulating factor receptors'1995 5,350,683'DNA encoding type II interleukin-1 receptors'1994 5,319,071'Soluble interleukin-1 receptors'1994 5,296,592'Process for purifying interleukin-1 receptors'1994 5,180,812'Soluble human interleukin-1 receptors, compositions and method of use'1993 5,081,228'Interleukin-1 receptors'1992 4,968,607'Interleukin-1 receptors'1990

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1990–2016Patents assigned to IMMUNEX CORP (62)· patent assignee history

1990–2016Based in Seattle, WA, US· patent location history

2011–2014Patents assigned to AMGEN INC (5)· patent assignee history

2012–2013Patents assigned to SIMS JOHN E (4)· patent assignee history

2012–2013Patents assigned to COCHRANE DUNCAN (2)· patent assignee history

2012–2013Patents assigned to CONROY LOUISE (2)· patent assignee history

2021Based in Littleton, CO, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMUNEX CORP	62	1990–2016
AMGEN INC	5	2011–2014
SIMS JOHN Eself	4	2012–2013
COCHRANE DUNCAN	2	2012–2013
CONROY LOUISE	2	2012–2013

Locations

Location	Patents	Span
Seattle, Washington, US	67	1990–2016
Littleton, CO, US	1	2021